Dror Bashan - 19 Dec 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: PLX
Reported as of: 19 Dec 2025
Net transaction value: +$101,360
SEC form: 4
Accepted by SEC: 23 Dec 2025, 07:25:58 UTC
Prior SEC filing: 04 Sep 2025
Next SEC filing: 04 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Joseph R. Magnas, Attorney-in-Fact

Key filing fact

Dror Bashan filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 23 Dec 2025.

Key facts

This page summarizes Dror Bashan's Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Dec 2025, 07:25.

Change

Previous filing in this sequence was filed on 04 Sep 2025.
Current net transaction value: +$101,360.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001781450 Primary reporting owner

Bashan Dror

Relationship: PRESIDENT AND CEO, Director
Address: C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Signature date: 23 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLX transaction

Common Stock

Purchase

Transaction value: $101,360
Shares: +56,000
Change %: +42%
Price: $1.81
Shares after: 188,516
Date: 19 Dec 2025
Ownership: Direct

PLX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,344,418
Date: 19 Dec 2025
Ownership: By Trust
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.